Occupier

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business

20 Jul 2021

Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, and other institutional and... Read more

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer

15 Jul 2021

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer Company to be led by award winning, cell therapy expert as it aims to unlock an expansive therapeutic target space by decoding natural T-cell responses in both oncology and autoimmune diseases. Oxford, UK, 15 July 2021 – T-Cypher Bio (‘T-Cypher’, or ‘the Company’), a rapidly emerging private biotech company pioneering a novel approach to TCR therapeutics... Read more

Etcembly establishes new lab & office space at TOSP

08 Jul 2021

Etcembly establishes new lab & office space at TOSP Immune-focused machine learning firm joins leading AI cohort on Park Oxford, UK, July 8 2021 – Etcembly Ltd, a machine learning biotech that is decoding immune pattern recognition of T cell receptors, has moved into more than 1,000 sq ft of new laboratory and office premises within The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The... Read more

Nature Biotechnology publishes ATDBio & University of Oxford single-cell sequencing research

01 Jul 2021

Nature Biotechnology publishes ATDBio & University of Oxford single-cell sequencing research Better understanding of disease possible with accurate full length identification of all messenger RNA in a cell Oxford, UK, July 1 2021 – Research on improved techniques for single-cell RNA sequencing by ATDBio, a leader in complex oligonucleotide synthesis, and a research team at the Botnar Research Centre, University of Oxford, has been... Read more

Orbit Discovery Appoints Dr Neil Butt as Chief Executive Officer

29 Jun 2021

Oxford, United Kingdom, June 29, 2021: Orbit Discovery Ltd (“Orbit”), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil Butt as Chief Executive Officer. With an extensive track record in commercialising proprietary drug discovery platforms, Dr Butt joins Orbit to oversee the Company’s development into a service driven drug... Read more

News